Expert consensuses suggest continuing SGLT-2 inhibitors in patients with recurrent urinary tract infections if there is an indication and exercising caution in those with a history of complicated recurrent urinary tract infections as well as chronic indwelling Foley catheters, but this is not an absolute contraindication. The gene discussed is SLC5A2; the disease is urinary tract infection.